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ABSTRACT 
 
Gene therapy is a promising emerging therapeutic modality for the treatment 
of cardiovascular diseases and hereditary diseases that afflict the heart. 
Hence, there is a need to develop robust cardiac-specific expression modules 
that allow for stable expression of the gene of interest in cardiomyocytes.  We 
therefore explored a new approach based on a genome-wide bio-informatics 
strategy that revealed novel cardiac-specific cis-acting regulatory modules 
(CRMs). These transcriptional modules contained evolutionary conserved 
clusters of putative transcription factor binding sites that correspond to a 
‘molecular signature’ associated with robust gene expression in the heart. We 
then validated these cardiac-specific CRMs in vivo using an adeno-associated 
viral vector serotype 9 (AAV9) that drives a reporter gene from a 
quintessential cardiac-specific myosin heavy chain (MHC) promoter. Most 
de novo designed cardiac-specific CRMs resulted in a  >10-fold increase in 
cardiac gene expression. The most robust CRMs enhanced cardiac-speciific 
transcription 70 to 100-fold.  Expression was sustained and restricted to 
cardiomyocytes. We then combined the most potent CS-CRM4 with a 
synthetic heart and muscle-specific promoter (SPc5-12) and obtained a 
significant 20-fold increase in cardiac gene expression compared to the 
cytomegalovirus promoter. This study underscores the potential of rational 
vector design to improve the robustness of cardiac gene therapy. 
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LIST OF ABBREVIATIONS 
AAV: adeno-associated virus; BLI: bioluminescent imaging; CRM: cis-
regulatory module; Casq: calsequestrin; CS-CRM: cardiac-specific cis-
regulatory module; ChIP: chromatin immunoprecipitation; CMV: 
cytomegalovirus; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GFP: 
green fluorescent protein; DDM: differential distance matrix; HFH1: 
Hepatocyte nuclear factor 1 homologue 1; HNF: hepatic nuclear factor; ITR: 
inverted terminal repeats;MHC: alpha myosin heavy chain; MDS: 
multidimensional scaling; mRNA: messenger RNA; MEF2: myocyte enhancer 
factor-2; qPCR: quantitative polymerase chain reaction; qRT-PCR: 
quantitative reverse transcriptase polymerase chain reaction; SRF: serum 
response factor; TFBS: transcription factor binding site; vg: vector genomes  
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INTRODUCTION 
 
Gene therapy offers promising prospects for the treatment of acquired 
cardiovascular diseases and hereditary disorders afflicting the heart. Long-
term expression and sustained therapeutic effects have been reported in 
animal models and the first clinical trial results targeting heart failure are 
encouraging 1–3. 
Nevertheless, there is a need to further improve the efficacy and safety of 
cardiac gene therapy applications. Increasing the vector dose typically boosts 
the therapeutic efficacy. However, this concomitantly increases the risk of 
possible undesirable side-effects. In particular, higher vector doses may 
trigger untoward adaptive or innate immune responses or result in direct 
cellular toxicity, depending on the vector type. For instance, one of the major 
risks associated with the use of adeno-associated viral vectors (AAV), relates 
to the induction of T cell-mediated immune responses against the vector 
capsid antigens displayed on major histocompatibility  class I antigens of the 
transduced cells4–6. This likely triggers the elimination of the gene-modified 
cells by the immune effector cells which in turn contributes to cellular toxicity 
and short-term gene expression. Most vectors used in clinical cardiac gene 
therapy rely on ubiquitously expressed promoter, such as the cytomegalovirus 
(CMV) promoter to drive the therapeutic gene1. However, this may not only 
result in cardiac gene expression but also provoke unwanted expression of 
the gene of interest in non-target cells, depending on the intrinsic tropism of 
the vector. This may in turn provoke undesirable cellular consequences and 
possibly also influence the immune response against the transgene product. 
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Indeed, it has been demonstrated that the inadvertent expression of the gene 
of interest in antigen-presenting cells (APCs), may provoke an untoward 
immune responses against the gene-modified target cells and/or the 
therapeutic transgene product7,8. The use of cardiac-specific promoters may 
improve transcriptional targeting in cardiomyocytes and potentially overcome 
some of the limitations of using ubiquitously expressed promoters9 
Importantly, these cardiac-specific promoters provide an added layer of 
control over transgene activity following systemic gene delivery. However, 
most cardiac-specific promoters (e.g.  myosin heavy chain, MHC promoter) 
typically yield lower levels of expression of the gene of interest. Hence, there 
is a need to further improve cardiac-specific gene therapy vectors using a 
multi-pronged approach that relies not only on optimizing ‘transductional’ 
targeting10–13 but also boosts expression by enhancing ‘transcriptional 
targeting’14. The development of more robust cardiac-specific vectors may 
allow for the use of lower and thus potentially safer vector doses for cardiac 
gene therapy applications. Most conventional methods of improving vector 
design, rely on haphazard ad hoc trial-and-error approaches whereby 
transcriptional enhancers are combined with promoters to increase  the levels 
of expression of the gene of interest and/or overcome transcriptional 
repression14,15. Moreover, the design of a given gene therapy vector is often 
based on the in vitro characteristics of its regulatory elements in cell lines. 
However, this approach is not always predictive as in vitro and in vivo vector 
performances do not always correlate16,17  
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In the current study, we validated an alternative strategy of improving 
transcriptional targeting to cardiomyocytes by ‘de novo computational design’. 
We therefore employed a comprehensive in silico strategy that relies on the 
genome-wide identification of transcriptional cardiac-specific cis-regulatory 
modules (CRM). These heart-specific CRMs contain a ‘molecular signature’ 
composed of clusters of transcription factor binding site (TFBS) motifs that are 
characteristic of highly expressed heart-specific genes. Moreover, this 
comprehensive computational analysis takes into consideration evolutionary 
conserved transcriptional regulatory motifs, which is particularly relevant in 
anticipation of clinical translation. Most importantly, these cardiac-specific 
CRMs boost transcriptional targeting after cardiac gene therapy up to 100-
fold. This type of multi-disciplinary approach -at the nexus of genomics, 
computational biology and gene therapy- remain largely unexplored, which 
underscores the novelty of the current study. Consequently, this approach 
offers unique opportunities to generate more robust cardiac-specific gene 
therapy vectors with potentially broad implications for the field. Furthermore, 
the validation of these heart-specific CRMs provides new insights into the 
molecular determinants underlying transcriptional control in cardiomyocytes. 
RESULTS  
 
Computational de novo design of heart-specific CRMs  
To design robust cardiac-specific gene therapy vectors, we relied on a multi-
step computational approach that allowed us to identify evolutionary 
conserved cardiac-specific CRMs (CS-CRMs) associated with genes that are 
highly expressed in the heart (Fig. 1). This in silico strategy was initially 
developed to identify CRMs associated with differential gene expression 
Ac
ce
pte
d m
an
us
cri
pt
ACCEPTED ARTICLE PREVIEW 
© 2014 The American Society of Gene & Cell Therapy. All rights reserved 
following specific in vitro stimuli18.  However, to our knowledge, this type of 
bio-informatics analysis had not yet been explored in the context of gene 
therapy and had not yet been validated in vivo. One of the unique features of 
this computational strategy is that it takes into account not only the over-
representation of a given TFBS but also its context-dependent co-occurrence 
with other TFBS on a genome-wide scale18. This comprehensive genome-
wide in silico analysis allowed us to take into account the actual context of the 
TFBS that are part of these transcriptional modules. 
 
Eight different CS-CRMs ranging from size of 117 bp to 689 bp were identified 
for the heart (Table 1 & Table S1, Figure S1). These CS-CRMs comprised 
binding sites for 8 different TFs including SRF, CTF/NF1, MEF2, RSRFC4, 
COUP-TF1, HFH1, HNF3and HNF3 (Table 1). The CS-CRM (i.e. CS-
CRM1 to CS-CRM8) correspond to TFBS clusters in the promoters of the 
following heart-specific genes: Myl3 (CS-CRM1), Brd7 (CS-CRM2) Myl2 (CS-
CRM3), Casq2e1 (CS-CRM4), Casq2e2 (CS-CRM5), Ankrd1e1 (CS-CRM6), 
Ankrd1e2 (CS-CRM7) and Ankrd1e3 (CS-CRM8) (Table 1). These distinct 
CS-CRMs contain a ‘molecular signature’ that are characteristic of genes that 
are highly expressed in the heart. Most CRMs contain identical TFBS but 
each CRM is unique with respect to their specific arrangement. The CS-CRMs 
were evolutionary conserved among 44 divergent species, suggesting strong 
selection pressure to maintain these particular TFBS combinations for high 
cardiac-specific expression.  We have shown the corresponding CRM 
sequences from a few selected species (Table S1 & Figure S1). This 
evolutionary conservation increases the likelihood that the performance of the 
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CRMs is preserved following gene therapy in humans. This may ultimately 
reduce attrition rate in gene therapy clinical trials. 
 
In vivo validation of cardiac-specific CRMs 
To validate the de novo designed CS-CRM in vivo, we generated adeno-
associated vectors (AAV) that expressed the humanized green fluorescent 
reporter protein (GFP) from a chimeric promoter. This promoter was 
composed of the heart-specific -myosin heavy chain (MHC) promoter 
linked to the different CS-CRM (Fig.  2a). We selected the AAV9 serotype to 
obtain efficient cardiac gene transfer after intravenous injection of 1011 vg in 
C57Bl/6 mice. Seventy percent of the de novo designed CS-CRM (5 out of 8: 
i.e. CS-CRM1, CS-CRM4, CS-CRM6, CS-CRM7 and CS-CRM8) resulted in a 
significant >10-fold increase (p<0.05) in transcription compared to the control 
without CS-CRM (Fig 3a & b), consistent with the increase in GFP protein 
expression levels (Fig 2b-2d). In particular, the CS-CRM4 and CS-CRM7 
elements resulted in a significant 100 and 70-fold (p< 0.01) increase in GFP 
mRNA expression respectively, compared to the control without CS-CRM (Fig 
3a & b). These two CS-CRMs share very similar types of TFBS, such as 
MEF2, RSRFC4, HFH1, NF1, HNF3 and HNF3 but differ in their specific 
arrangement. Consequently, these selected CS-CRM yielded the highest GFP 
protein expression levels in the heart (Fig 4 a-d). This was confirmed at two 
different vector doses (Fig 2b & Figure S2). Overall, the mRNA levels 
correlated strongly with the GFP fluorescence. Cardiac specificity was 
maintained since GFP mRNA and protein expression was absent or limited in 
any other organ or tissue, (Fig 4, 5a-b & Figure S3 a-h). All the AAV9-CS-
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CRM-MHC-GFP constructs resulted in stable cardiac gene transfer with 
comparable efficiencies (Figure S4 a-b), confirming that the differences in 
reporter gene expression directly reflect the differences in potency of the 
respective CS-CRM. Furthermore, though the AAV9 vectors resulted in 
significant number of vector genomes in different tissues besides heart, 
including liver, lungs, skeletal muscle and to a lesser extent in spleen, kidney 
and brain (Fig 6a & b), expression was restricted to the heart and more 
specifically to cardiomyocytes as confirmed by immunohistochemistry for 
troponin-T and connexin-43 (Fig 6c & d). These in vivo data validate the bio-
informatics algorithm and establish proof-of-concept that the de novo design 
of cardiac-specific CS-CRM resulted in robust cardiomyocyte-specific 
expression following gene therapy. Finally, we demonstrated the binding of 
MEF2, SRF and HNF3 on the most potent CS-CRM4 element by chromatin 
immunoprecipitation (ChIP) using heart from mice that were injected with AAV 
vectors containing CS-CRM4 (Fig. 2a & Figure S2). The ChIP assays 
revealed a specific enrichment of the MEF2, SRF and HNF3 TFs on CS-
CRM4. In particular, in the case of MEF2, a robust 14-fold enrichment of CS-
CRM4 over the negative control was apparent. In addition, a 9.5 and 4.5-fold 
enrichment was observed for SRF and NHF3, respectively (Fig. 6e). This 
provided independent experimental confirmation of the in silico predicted 
putative TFBS that are located in the CS-CRM4 element.  
 
Combining synthetic promoters with cardiac-specific CRMs 
Next, we combined the most potent CS-CRM4 element with a synthetic 
promoter that is known to confer high cardiac and skeletal muscle-specific 
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expression (i.e. SPc5-12)16 and tested its impact on gene expression in these 
tissues. This chimeric synthetic CS-CRM4/SPc5-12 promoter was used to 
express luciferase from a self-complementary AAV9 (scAAV9), that further 
increases transduction compared to ssAAV. The AAV terminal repeat (TR) 
mutant generates self-complementary vectors to overcome the rate-limiting 
step to transduction in vivo19–21. We injected 1010 vg scAAV9-luciferase 
vectors in adult severe combined immune deficient (SCID) mice and 
determined luciferase expression by bioluminescent imaging (BLI) 2 and 4 
weeks post-injection (Fig. 7a). Ex vivo analysis of the organs was performed 5 
weeks post-injection (Figure S5 & S6). Comprehensive comparative analysis 
by BLI revealed that this de novo designed chimeric synthetic CS-
CRM4/SPc5-12 combination was the most potent compared to any of the 
other promoters tested (Fig 7b, 7c & Figure S5). In particular, a robust and 
significant 20-fold increase in cardiac expression was obtained using the CS-
CRM4/SPc5-12 promoter compared to the cytomegalovirus (CMV) promoter. 
CMV is commonly used in cardiac gene therapy clinical applications and 
serves as the ‘gold standard’ given its robust expression in cardiomyocytes. 
The level of cardiac-specific luciferase gene expression driven from the CS-
CRM4/MHC promoter was comparable to that of CMV (Fig. 7b, Fig. 7c & 
Figure S5). Moreover, CS-CRM4/SPc5-12 was also more robust than the CS-
CRM4/MHC chimeric promoter, yielding a significant 19-fold increase in 
luciferase activity (Fig. 7b, Fig. 7c). Finally, we demonstrated that the chimeric 
synthetic CS-CRM4/SPc5-12 promoter resulted in a nearly 5-fold increase in 
cardiac gene expression compared to SPc5-12 whereas only a slight or no 
increase in skeletal muscle expression was apparent (Fig. 7b & c). The 
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preferential increase in cardiac expression as opposed to muscle by the CS-
CRM4 element is consistent with the preferential binding of cardiac-specific 
TFs on CS-CRM4  (Fig. 6e). This implies that the extent of the increase by the 
CS-CRM is depending, at least in part, on the promoter used to drive the gene 
of interest (i.e. MHC vs. SPc5-12). Reporter gene expression was absent in 
most of the other organs and tissues (i.e. kidney, spleen, brain and 
diaphragm) (Figure S6). Nevertheless, we observed minor expression in the 
lungs of the mice injected with the vector containing the SPc5-12 promoter. 
Moreover, expression of the reporter gene was observed in the liver (Figure 
S6 & S7). These observations challenge the prevailing assumption that the 
synthetic SPc5-12 promoter is only expressed in heart and skeletal muscle.   
 
We subsequently injected the AAV9sc-CS-CRM4/SPc5-12 vector (5x1010 vg 
i.v.) into 4 week old C57BL/6 mice (male) and monitored long-term luciferase 
expression for up to 8 weeks post-injection. Similar results were now obtained 
in immune-competent C57BL/6 mice as described above in the SCID model 
(Fig. 8 & Figure S8). This confirms that luciferase expression does not trigger 
any untoward immune reactions and/or that the expression is not silenced, 
consistent with the long-term persistence of the AAV transduced luciferase-
expressing cells.  The highest level of cardiac gene expression was obtained 
with the AAV9sc-CS-CRM4/Spc5-12 vector, yielding a significant 19-fold 
increase (at 8 weeks) compared to AAV9sc-CMV consistent with the results 
obtained in SCID mice. Moreover, a significant 2-fold increase in luciferase 
expression was apparent compared to AAV9sc-Spc5-12.   
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DISCUSSION 
 
The current study explores the use of bio-informatics to improve the efficiency 
of cardiac gene therapy. Based on a comprehensive genome-wide in silico 
analysis, we discovered evolutionary conserved clusters of TFBS motifs that 
correspond to cardiac-specific CRMs.  The corresponding genes linked to 
these CS-CRMs were all highly and specifically expressed in the heart. This 
indicates that a specific ‘TFBS signature’ characterizes robust cardiac-specific 
expression. Using cardiotropic AAV9 vectors, we validated experimentally that 
the majority of these CRMs resulted in a significant >10-fold increase in gene 
expression in the heart, while maintaining a high degree of cardiac selectivity. 
The increased protein expression levels were consistent with an increased 
transcriptional activity. In particular, the most robust CS-CRM elements (i.e. 
CS-CRM7 and CS-CRM4) resulted in a 70-to 100-fold increase in cardiac 
transcription from the quintessential cardiac MHC promoter. It is therefore 
particularly encouraging that these CRMs effectively boost the performance of 
the αMHC promoter, since it has been used previously to coax gene 
expression in the heart following gene therapy9. Moreover, we demonstrated 
that the combination of the CS-CRM4 element with a synthetic heart/muscle-
specific promoter (i.e. SPc5-12) resulted in a 20-fold increase in cardiac 
expression levels compared to when the CMV promoter was used. This has 
important translational implications since the CMV promoter is widely used in 
gene therapy clinical trials for heart failure, including the promising CUPID trial 
that is based on AAV1-SERCA2a myocardial transduction2,22. Consequently, 
this novel synthetic chimeric CS-CRM4/SPc5-12 promoter constitutes an 
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attractive alternative to CMV. It may be well suited to boost the performance 
of AAV vectors in future gene therapy clinical trials for heart failure and 
hereditary disorders that affect heart and skeletal muscle (e.g. Duchenne 
muscular dystrophy). 
 
Consequently, higher expression levels can be achieved with the same 
amount of vector. This also implies that a therapeutic effect could potentially 
be achieved at lower vector doses, which would ease the manufacturing 
constraints and minimize the risk of possible immune complications.  In 
particular, the use of lower vector doses may minimize the risk of triggering 
AAV-specific cytotoxic T cell immune responses5,23,24. These cellular immune 
responses were previously shown to eliminate AAV-transduced cells, at least 
in liver4–6,25,26. To facilitate transduction in the face of pre-existing anti-AAV 
antibodies2,22 would be more challenging and would require AAV capsid 
decoys instead or plasma-exchange27,28. In addition to the use of an optimal 
CS-CRM/synthetic promoter combination, the AAV serotype itself significantly 
impacts on cardiac tropism and expression10–13. The optimization of cardiac 
gene therapy therefore requires optimal cardiotropic AAV serotypes and the 
use of optimal cardiac-specific regulatory elements, specifically tailored to 
maximize expression of the gene of interest in cardiomyocytes. In future 
studies, we will explore and validate the use of these optimized AAV vectors 
for delivery and expression of therapeutic genes in preclinical models of 
cardiovascular disease. 
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Another limitation of conventional vector design is that the typical regulatory 
elements are often quite large, limiting the size of the transgene that can be 
packaged into a viral vector.  Typically, trimming down promoter sizes results 
in loss of potency and/or specificity. In contrast, our study shows that potency 
and specificity was maintained even when selecting small-size CS-CRMs 
(<300bp). Given their small size, these CS-CRMs could be used in 
conjunction with relatively large therapeutic transgenes and/or can be readily 
accommodated in scAAV vector designs, which have an intrinsic limited 
packaging capacity of 2.5 kb, to overcome the rate-limiting transduction steps 
in vivo 19–21. 
 
The present in silico approach does not only allow for the identification of 
TFBS that are over-represented in cardiac-specific CRMs but it also takes into 
consideration the specific context of these TFBS. Consequently, the current 
analysis is more comprehensive and allows for the identification of cardiac-
specifc TFBS elements that tend to cluster together in CS-CRMs of genes 
that are highly expressed in the heart. It therefore takes into account the 
actual context-dependent TFBS interactions from a broad genome-wide 
perspective, instead of just relying on the over-representation of a single 
TFBS element18. Our previous studies had shown that the present in silico 
analysis is more reliable, compared to other data-mining strategies that 
typically rely solely on the over-representation of a given TFBS, regardless of 
its context, as discussed previously18. The current computational approach 
that defines the CS-CRMs has been further improved beyond the initial 
description of the algorithm18, by taking into account phylogenetic  
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conservation of the TFBS clusters. This increases the likelihood that the 
superior performance of the CS-CRMs is maintained upon clinical translation. 
Furthermore, the current study corroborates the algorithm and establishes a 
causal relationship between these evolutionary conserved TFBS clusters in 
the CS-CRMs and high cardiac-specific gene expression. In contrast, the 
previously published bioinformatics approach was applied in a different 
context and merely established correlations between TFBS clusters and 
differentially expressed genes following a given physiologic stimulus in vitro 18. 
Moreover, direct proof of the impact of such TFBS clusters on gene 
expression levels in vivo was lacking. The current study overcomes this 
limitation by in vivo gene transfer, hereby providing direct experimental in vivo 
validation of the genome-wide computational analysis. Though the large 
majority of the selected CS-CRMs resulted in a significant increase in 
expression of the gene of interest, a few elements had a more limited impact. 
It is therefore possible that other unknown factors that were not taken into 
account in the computational analysis, may have influenced gene expression 
levels, such as epigenetic factors, chromatin remodeling and/or the spacing 
between a given CS-CRM and the promoter/TATA box and their respective 
orientation on the DNA helix, It is beyond the scope of the present study to 
analyze this further but it sets the stage to further refine the computational 
analysis. The present study demonstrates that the CS-CRM elements result in 
a significant increase in cardiac gene expression when used in conjunction 
with either the αMHC promoter or the synthetic SPc5-12 promoter. This 
suggests that these CS-CRM elements may also effectively boost cardiac 
gene expression in combination with other heart-specific promoters but this 
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would need to be verified experimentally on a case-by-case basis. αMHC is 
widely expressed in normal rodent hearts, justifying the use of the 
corresponding αMHC promoter to achieve cardiomyocyte-specific gene 
expression in mouse models. However, failing rodent hearts have a 
propensity for βMHC instead of αMHC. In humans, MHC expression in the 
failing heart is skewed towards βMHC instead of αMHC. Other promoters that 
are highly expressed in the failing human heart would therefore need to be 
considered for clinical gene therapy applications. The SPc5-12 promoter by 
itself and its CS-CRM4/SPc5-12 derivative constitute attractive alternatives. 
 
The present study has broad implications for the design of better gene 
therapy vectors that target different diseases. Our results indicate that in silico 
‘rational vector design’ may therefore pave the way towards a more 
comprehensive approach towards vector optimization with broad implications 
to improve the efficacy and safety of gene therapy. Indeed, we have recently 
confirmed that the same computational approach can be employed to identify 
liver-specific and skeletal muscle-specific CRMs that boost the performance 
of gene therapy vectors in mouse disease models (i.e. hemophilia, 
phenylketonuria) or non-human primates, which is consistent with our present 
findings29–31. In particular, in these studies, we observed a significant 10 to 
100-fold increase in liver-specific gene expression when the corresponding de 
novo designed tissue-specific CRMs were employed. Our findings may 
ultimately impact not only on the clinical translation of gene therapy but also 
on fundamental biological and transgenic studies that rely on the use of robust 
tissue-specific gene expression32,33. 
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METHODS 
 
Identification of cardiac-specific CRMs by computational analysis 
A computational sequential approach (Fig. 1) was used to identify tissue-
specific CRMs: (1) identification of cardiac-specific genes that are highly 
expressed based on statistical analysis of micro-array expression data of 
normal human heart tissues; (2) extraction of the corresponding promoter 
sequences from publicly available databases (3) identification of the 
regulatory modules and the TFBS using a differential distance matrix (DDM)/ 
multidimensional scaling (MDS) approach18 (4) searching the genomic context 
of the highly expressed genes for evolutionary conserved clusters of TFBS 
(i.e. CRMs). A detailed outline of the bio-informatics approach is outlined in 
the Supplementary Materials & Methods. 
Generation of CRM constructs 
The cardiac-specific CRMs (CS-CRM1 to CS-CRM8) (Table 1) were 
synthesized by conventional oligonucleotide synthesis.  The different CS-
CRM were cloned upstream of the -myosin heavy chain (MHC)9,  in the 
context of an adeno-associated viral vector (AAV) backbone (Fig. 2a). 
Additionally,  the CS-CRM4 was cloned upstream of the novel synthetic 
promoter SPc5-1216 using a self-complementary AAV (scAAV) backbone19. 
The luciferase (Luc) cDNA was used to substitute the GFP as reporter gene. 
Transgene expression was compared with two other designed vectors, one 
containing the CMV promoter instead of the SPc5-12 and a reference group, 
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in which the CS-CRM was removed. Cloning details are available upon 
request. 
 
AAV vector production and purification  
AAV vectors were prepared as previously described12. Genome-containing 
vectors and empty AAV capsid particles were purified by cesium chloride 
gradient. For all vector, the titer (in viral genomes (vg)/ml) was determined by 
qRT-PCR. Typically, for all vectors we achieved titers in the normal range of 
2-5x1012 vg/ml.   
 
Animal procedures 
All animal procedures were approved by the institutional animal ethics 
committee of the University of Leuven and Vrije Universiteit Brussels. For the 
in vivo screening of the CS-CRMs, two-days old C57BL/6 mice were injected 
with vectors containing the different CS-CRM elements (2X1010 to 3X1011 
vg/mouse) via periorbital vein. Mice were euthanized by cervical dislocation 
after inhaled anesthesia using Isofluorane at 4% in a chamber (depth of 
anesthesia was evaluated by loss of purposeful voluntary movement and loss 
of response to reflex stimulation) 5 weeks post-injection and organs were 
harvested and examined. For the BLI analysis (see below), 1010 vg scAAV9-
luciferase vectors were injected in adult severe combined immune deficient 
(SCID) mice. 
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mRNA analysis  
qPCR analysis from mRNA extracted from different organs collected were 
performed. All results were normalized to mRNA levels of the endogenous 
murine glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene.  
 
Transduction efficiency and vector biodistribution 
Transduction efficiency was evaluated by quantifying the GFP transgene copy 
numbers in the different tissues, as described previously34. The results were 
expressed as mean AAV copy number/100 ng of genomic DNA. The qPCR 
standard consisted of serially diluted plasmids of known quantity. 
 
Chromatin immunoprecipitation assays (ChIP assays) 
Genomic DNA regions of were isolated by using specific ChIP grade 
antibodies35,36. Quantitative PCRs (qPCRs) were carried out on speciﬁc 
genomic region, the resulting signals were normalized for primer efﬁciency by 
carrying out qPCR for each primer pair using input DNA. Primer sequences 
include for positive control and negative control are available upon request.  
 
Immunohistochemistry  
Following paraffin embedding protocol, the heart samples were analyzed 
using  anti-troponin-T (1:100, Thermo Scientific, Waltham, MA, USA)37 as 
primary antibody and biotinylated secondary antibody. After PBS washings 
and incubation with DyLight 549-Streptavidin the slides were mounted with 
fluorescent mounting medium (Without counterstain).  Immunostaining 
analysis for connexin 43 and GFP from heart slides was conducted using 
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primary connexin 43 rabbit polyclonal antibody (Santa Cruz Biotechnology, 
Santa Cruz, USA) or anti-GFP goat polyclonal antibody (Abcam, Cambridge, 
USA)38,39. Nuclei were stained with DAPI (Invitrogen Co., Carlsbad, USA) 
 
 
Detection of luciferase transgene expression 
Luciferase expression was analyzed using an In vivo Photon Imager 
(Biospace, France) after intravenous injection of 50 μl luciferin substrate (150 
mg/kg, Promega). Representative in vivo bioluminescence transgene 
expression images were taken at 2, 4 and 8 weeks post vector injection. 
Subsequently at 5 and 8 weeks post viral vector injection, the organs were 
removed and bioluminescence signal was quantified during 5 min 
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TABLE LEGENDS 
 
Table 1. Transcription factor binding sites (TFBS) strongly associated with 
high cardiac-specific expression. Evolutionary conserved CS-CRM enriched in 
TFBS associated with high cardiac-specific expression. The CS-CRM 
designation, corresponding gene, size (in bp) and TFBS clusters are shown. 
Subscripts a, b or c refer to CS-CRM present at different locations within the 
same promoter of a given gene   
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TABLE 1  
Name Gene 
Length 
(bp) 
TFBS 
CS-CRM1  MyI3  150  
SRF, NF1, MEF2, RSRFC4, 
COUP-TF1, HFH1, HNF3α, 
HNF3β 
CS-CRM2 Brd7  689  HFH1, HNF3α, HNF3β, SRF, 
RSRFC4, NF1 
CS-CRM3 MyI2  183  HFH1, HNF3α, HNF1, MEF2, 
SRF, NF1, RSRFC4 
CS-CRM4  Casq2ea  219  
 
HNF3α, MEF2, SRF, NF1, 
RSRFC4, HNF3β, HFH1. 
CS-CRM5  Casq2eb  117  HNF3α, HNF3β, MEF2, NF1, 
HFH1 
CS-CRM6 Ankrd1ea 299  HNF3α, HNF3β, HNF1, HFH1 
CS-CRM7  Ankrd1eb 277  MEF2, HNF3α, HFH1, HNF3β, 
NF1 
CS-CRM8  Ankrd1ec 397  HFH1, HNF3α, MEF2, SRF, 
COUP-TF1, NF1, HNF3β. 
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FIGURE LEGENDS 
 
Figure 1. Multi-step in silico strategy. A computational approach was used 
to identify cardiac-specific CRMs. DDM/MDS: Distance difference 
matrix/Multidimensional scaling; TFBS: transcription factor binding site 
 
Figure 2. Validation of cardiac-specific cis-regulatory module (CS-CRM). 
(a) Schematic representation of AAV9-CS-CRM-MHC-GFP vector used in 
this study. The expression cassette was packaged in a single-stranded (ss) 
adeno-associated virus serotype 9 (AAV9), flanked by the 5’ and 3’ AAV2 
inverted terminal repeats (ITR). The -myosin heavy chain (MHC) promoter 
drives the humanized recombinant green fluorescent protein (GFP) reporter 
transgene. The cardiac-specific CS-CRM (i.e. CS-CRM1 to CS-CRM8) were 
cloned upstream of the -MHC promoter. The -globin intron and bovine 
growth hormone polyadenylation site (pA) are also indicated. The control 
vector AAV9-MHC-GFP is identical to AAV9-CS-CRM-MHC-GFP but does 
not contain any CS-CRM elements. Representative results at one vector dose 
(1011 vg/mouse) were shown (see below). The expression pattern was 
confirmed when the experiment was repeated at different vector doses (i.e. 
3x1011 vg/mouse and 2x1010 vg/mouse) (data not shown) (b) Fluorescent 
imaging of intact hearts of mice injected with 1011 vg/mouse of AAV9-CS-
CRM-MHC-GFP containing the different CS-CRM (i.e. CS-CRM1 to CS-
CRM8) or the AAV9-MHC-GFP vector without CS-CRM as a control 
(indicated as no CS-CRM). Panels are shown at 12.8x magnification, 10 s 
constant exposure time. (c) Longitudinal tissue fragments of the heart were 
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excised using a scalpel and put into a 96-well plate. This allowed us to 
acquire fluorescent composite images of the heart tissue by scanning the 
entire tissue fragment in a semi-automatic fashion using the Zeiss Axiovert 
200 inverted microscope. Mice were injected with the different CRM vectors 
shown in (b).Panels are shown at 5x magnification, 2 s exposure time.  (d) 
Confocal microscopy of intact myocardium of mice injected with 1011 
vg/mouse of AAV9-CS-CRM-MHC-GFP containing the different CS-CRM 
(i.e. CS-CRM1 to CS-CRM8) or the AAV9-MHC-GFP vector without CS-
CRM as a control (indicated as no CS-CRM). A representative confocal scan 
is shown. There was no background fluorescence in PBS-injected mice (Fig. 
S2). Pictures were taken at 10x magnification (n=3 mice per group)  
 
Figure 3. Validation of cardiac-specific cis-regulatory module (CS-CRM). 
(a) Semi-quantitative RT-PCR and (b) quantitative real-time RT-PCR of GFP 
mRNA expression levels in the heart (mRNA was purified from each mice, 3 
mice per group and 3 samples of each organ were analyzed per qPCR in 
triplicate, averages are presented) 6 weeks after intravenous injection of the 
AAV9-CS-CRM-MHC-GFP vectors (1011 vg/mouse) containing the different 
CS-CRM elements (i.e. CS-CRM1 to CS-CRM8) compared to AAV9-MHC-
GFP control. Relative cardiac mRNA expression levels (mean + s.e.m.) are 
shown. MW:  molecular weight marker; H2O: control sample. GAPDH is 
shown for comparison in the semi-quantitative RT-PCR and it was used for 
normalization in the quantitative real-time RT-PCR .  
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Figure 4. Cardiac specificity of the CS-CRM. Fluorescent (a, c) and 
confocal microscopy (b, d) images of representative sections from selected 
tissues of the mice injected with AAV9-CS-CRM4-MHC-GFP (a, b) or AAV9-
CS-CRM7-MHC-GFP (c, d) (1011 vg/mouse) (n=3). A tissue fragment of 
each organ was excised using a scalpel and put into a 96-well plate. This 
allowed us to acquire fluorescent composite images of the heart tissue by 
scanning the entire tissue fragment in a semi-automatic fashion using the 
Zeiss Axiovert 200 inverted microscope.  Panels are show at 5x magnification, 
2 s exposure time (a, c). Representative images by confocal microscopy are 
shown at 10x magnification (b, d). Six images were obtained from different 
fragments of each organ, n = 3 mice per group; a representative image is 
shown.  
 
Figure 5. Cardiac specificity of the CS-CRM. (a) Semi-quantitative RT-PCR 
and (b) quantitative real-time RT-PCR of GFP mRNA expression levels in 
different organs 6 weeks after intravenous injection of the AAV9-CS-CRM4-
MHC-GFP vectors (1011 vg/mouse) (n = 3). Expression levels (mean + s.d.) 
relative to the corresponding organ of the mice injected with the control group 
are shown.  
 
Figure 6. Biodistribution and transduction efficiency. Biodistribution and 
transduction efficiency (a,b)  analysis in different organs of mice (n = 3) 
injected with AAV9-CS-CRM4-MHC-GFP (1011 vg/mouse) (a) or AAV9-CS-
CRM7-MHC-GFP (1011 vg/mouse) (n= 3) (b) determined by qPCR using 
vector specific primers. Relative to a standard curve of known vector copy 
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numbers (mean + s.d.) are shown. (c, d) Heart sections of mice injected with 
AAV9-CS-CRM4-MHC-GFP (1011 vg/mouse) were subjected to 
immunostaining for troponin-T (TNNT) (red), connexin-43 (Cnx43) (red) and 
GFP (green). Nuclei were stained with DAPI (blue). Note the peri-cellular 
location of Cnx43 on cardiomyocytes consistent with its participation in inter-
cellular gap junctions essential for Ca2+ handling. (e) Chromatin immuno-
precipitation (ChIP) assay on heart of mice injected with AAV9-CS-CRM4-
MHC-GFP (1011 vg/mouse). Antibodies specific to HNF3, MEF2 or SRF1 
and PCR primers specific for the corresponding TFBS were used. In 
particular, PCR primers were designed to amplify a region within the vector 
corresponding to CS-CRM4 (that binds HNF3, MEF2 and SRF1), a positive 
control region in the genome corresponding to the cognate TFBS elements 
(+) or and untranscribed region on chromosome 6 as negative control (-). 
Binding events per 103 cells were determined for each of the corresponding 
primers pairs. Significant differences compared to the negative control were 
indicated (t-test, *p ≤0.05, mean + s.d.). 
 
Figure 7. Whole body bioluminescence imaging and quantitation of 
luciferase expression in heart and skeletal muscle in SCID mice. (a) In vivo 
bioluminescence imaging of transgene expression in SCID mice injected 
intravenously with scAAV9-luciferase vectors (n=4 mice per group) containing 
the different promoters (i.e. CS-CRM4/αMHC; SPc5-12; CMV; CS-CRM4/SPc 5-
12). Images were taken 2 and 4 weeks post injection. Whole body 
bioluminescence  imaging were represented based on a color scale, showing 
intensities ranging from 5.22X103 (blue) – 6.82X105 (red) ph/s/cm2/sr. (b) Ex vivo 
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determination of luciferase expression in heart and skeletal muscles. Values 
were expressed as total flux (photons/sec/cm2/sr) and (c) fold-difference in total 
flux with respect to AAV9sc-CS-CRM4/αMHC vector. The fold-difference was 
indicated above the graph for the AAV9sc-CS-CRM4/SPc5-12 vector. Values 
were expressed as mean + s.e.m. (n=3 mice per group). Gastroc.: 
gastrocnemius; Quads: quadriceps 
 
Figure 8.  Whole body bioluminescence imaging and quantitation of 
luciferase expression in heart and skeletal muscle in C57Bl/6 mice. (a) In 
vivo bioluminescence imaging of luciferase expression in C57BL/6 mice 
injected intravenously with scAAV9-luciferase vectors (n=3 mice per group, 
5x1010 vg/mouse) containing the different promoters (i.e. SPc5-12; CMV; CS-
CRM4/SPc 5-12). Images were taken 2, 4 and 8 weeks post injection. Whole 
body bioluminescent images were represented based on a color scale, 
showing intensities ranging from 1.26X106 (blue) – 1.45X107 (red) ph/s/cm2/sr. 
(b) Ex vivo bioluminescence imaging of harvested heart and skeletal muscles 
from C57BL/6 mice injected intravenously with the scAAV9-luciferase vector 
(n=3 mice per group, dose: 5x1010 vg/mouse) containing the different 
promoters (i.e. SPc5-12; CMV; CS-CRM4/SPc 5-12). Images of the harvested 
tissues and organs were taken 8 weeks post injection. Bioluminescent images 
of all respective tissues and organs were represented based on a color scale, 
showing intensities ranging from 8.34X104 (blue) – 1.28X106 (red) ph/s/cm2/sr. 
(c) Quantification of luciferase expression ex vivo in harvested heart and 
skeletal muscles at week 5 and week 8 from C57BL6 mice injected 
intravenously with scAAV9-luciferase vectors (n=3 mice per group, dose: 
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5x1010 vg/mouse) containing the different promoters (i.e. SPc5-12; CMV; CS-
CRM4/SPc 5-12). Values were expressed as mean + s.e.m. (n=3 mice per 
group). Gastroc.: gastrocnemius; Quads: quadriceps 
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